Tüdőrák: vizsgálatok itt: Magyarország
57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in MagyarországClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Budapest, Miskolc
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Budapest VIII, Budapest XII, Farkasgyepű, Törökbálint
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1/2. fázisBefejeződöttKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Where
- Budapest XII, Győr, Szolnok
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00 - No phaseBefejeződöttKEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Where
- Budapest, Győr, Szolnok
- Életkor
- 18 év and over
- People
- 1065 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165798 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Budapest Viii, Budapest XII, Debrecen, Edelény, Gyöngyös, Győr, Pécs, Szekesfehervar, Szekszárd, Törökbálint
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Budapest XII, Gyöngyös, Győr, Gyula, Kecskemét, Szekesfehervar, Szekszárd, Szolnok, Törökbálint
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Budapest VIII, Budapest XII, Debrecen, Gyöngyös, Győr, Pécs, Szekesfehervar, Szekszárd, Törökbálint
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Budapest XII, Gyongyos, Gyöngyös
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Budapest XII, Farkasgyepű, Gyöngyös, Szolnok
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 2. fázisTaking peopleNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Where
- Kecskemét, Szekesfehervar, Tatabánya, Törökbálint
- Életkor
- 18 év to 95 év
- People
- 630 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Kecskemét
- Életkor
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - 2. fázisFut, nem toborozA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Where
- Budapest XII, Győr, Szolnok
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06731907 · EU 2024-515772-12-00 - 1/2. fázisVisszavonvaA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Budapest
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 3. fázisTaking peopleSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Farkasgyepű, Gyula, Kaposvár, Kecskemét, Pécs, Szolnok, Tatabánya, Törökbálint
- Életkor
- 18 év and over
- People
- 1410 worldwide
- Run by
- Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Budapest VIII, Budapest XII, Gyöngyös, Pécs, Törökbálint
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 1/2. fázisNot yet taking people in MagyarországA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Budapest XII, Kecskemét, Szolnok
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Debrecen, Gyöngyös, Gyula, Kecskemét
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- Budapest XII, Deszk, Gyula, Kecskemét, Mátraháza
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 1/2. fázisTaking peopleA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Where
- Kalocsa
- Életkor
- 18 év and over
- People
- 118 worldwide
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- Budapest XII, Gyöngyös, Törökbálint
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - 3. fázisTaking peopleRoll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Budapest Viii, Budapest XII, Győr, Szekesfehervar
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00 - 3. fázisBefejeződöttStudy of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Gyöngyös - Mátraháza, Kecskemét, Zalaegerszeg
- Életkor
- 18 év and over
- People
- 355 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to join2024-515884-69-00 - 3. fázisFut, nem toborozStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Budapest XII, Gyöngyös, Törökbálint
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Budapest VIII, Budapest XII, Győr, Kecskemét
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - No phaseTaking peopleHealth for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
- Where
- Balatonfüred, Békéscsaba, Budapest, Csorna, Debrecen, Encs, Győr, Gyula, Hatvan, Jászszentlászló, Kaposvár, Kecskemét, Miskolc, Nyíregyháza, Orosháza, Pécs, Sopron, Szeged, Székesfehérvár
- Életkor
- 40 év and over
- People
- 15 000
- Run by
- Center for Molecular Fingerprinting Research Nonprofit LLC
See details and how to joinNCT07743021